Mount Olive, NJ, May 1, 2010 -- InSet Technologies Inc., a medical device company focused on providing drug delivery solutions, announced today the adoption of a new company name. The new name, Medasys Inc., creates a clearer association with the programmable infusion systems Medasys will market in the US.

The InSet name, along with various patents on technology associated with implantable programmable drug pumps, was acquired in 2005, when InSet was formed. In 2007, InSet received approval from the US FDA to conduct a clinical trial to validate the safety and efficacy of the Prometra Programmable Pump. Medasys’ first product, Prometra, is designed to be highly reliable, and very accurately deliver medicines to the intrathecal space that surrounds the spinal cord.

While data collection for the clinical trial will continue until the device obtains US FDA clearance, several abstracts have been presented to describe the clinical results. A published paper has also reported on clinical accuracy, safety, and efficacy experienced with drug delivery via the Prometra pump.

“As we await FDA approval, we are committed to meeting the needs of physicians and patients who would benefit from access to this life changing therapy” said Steve Adler, CEO of Medasys. FDA approval is anticipated later this year.

About Medasys
Medasys’ strategic goal is to become the leading implantable drug delivery company in the world. Founded in 2005, Medasys acquired a significant patent portfolio from Proven Process Medical Devices, an engineering team responsible for many of the early drug pump innovations of the 70s, 80s, and 90s. It received approval to conduct its first clinical trial in 2007, and is expecting to receive clearance by the FDA to market the device in 2010. Medasys has been granted over a dozen patents, and is focused on working closely with physicians to rapidly improve the capabilities of implantable drug delivery and management systems.
For more information see the Medasys web site at: http://www.MedasysPumps.com.

Forward Looking Statements
This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, reimbursement policies, commercialization of new technologies, intellectual property, and other factors.

Contact Medasys Inc.
Stephen Bowman, Vice President of Sales
(973) 426-9229
sbowman@medasyspumps.com